Accessibility Menu
Astellas Pharma Stock Quote

Astellas Pharma (OTC: ALPMF)

$10.90
(10.7%)
+1.05
Price as of October 20, 2025, 11:13 a.m. ET

KEY DATA POINTS

Current Price
$10.9
Daily Change
(10.7%) +$1.05
Day's Range
$10.8 - $10.9
Previous Close
$10.9
Open
$10.8
Beta
0.10
Volume
265
Average Volume
7,963
Market Cap
19.5B
Market Cap / Employee
$10.90M
52wk Range
$8.41 - $12
Revenue
-
Gross Margin
0.75%
Dividend Yield
4.68%
EPS
$0.31
CAPs Rating
-
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

Astellas Pharma Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
ALPMF-4.6%-10.19%-2.12%-61%
S&P+14.5%+93.32%+14.09%+570%

Astellas Pharma Company Info

Astellas Pharma, Inc. engages in the research, development, manufacture, import, and export of pharmaceutical products. Its products focus on therapeutic fields that include transplantation, immunology, infectious diseases, urology, oncology, neuroscience, diabetic complications, and metabolic diseases. The firm's global brands include Prograf, Vesicare, Protopic, Harnal, and Funguard. The company was founded by Kenji Yamanouchi in April 1923 and is headquartered in Tokyo, Japan.

News & Analysis

Financial Health

General

Q2 2025YOY Change
Revenue$3.50B15.3%
Gross Profit$2.62B17.5%
Gross Margin74.77%1.4%
Market Cap$17.20B1.7%
Market Cap / Employee$1.26M0.0%
Employees13.6K-7.5%
Net Income$473.54M96.2%
EBITDA$1.09B63.8%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q2 2025YOY Change
Net Cash$1.49B-20.8%
Accounts Receivable$4.63B26.7%
Inventory2.1K33.0%

Liabilities

Q2 2025YOY Change
Long Term Debt$3.86B13.2%
Short Term Debt$2.29B-32.8%

Ratios

Q2 2025YOY Change
Return On Assets2.44%1.9%
Return On Invested Capital5.24%-2.4%

Cash Flow

Q2 2025YOY Change
Free Cash Flow$297.90M19161.9%
Operating Free Cash Flow$386.54M323.1%

Valuation

MetricQ2 2024Q3 2024Q1 2025Q2 2025YoY Change
Price to Earnings167.8257.8952.0931.09-83.28%
Price to Book1.921.651.841.705.98%
Price to Sales1.761.421.381.35-13.12%
Price to Tangible Book Value-11.93-13.21-18.25-100.19982.63%
Price to Free Cash Flow TTM83.85319.9574.2937.12-69.85%
Enterprise Value to EBITDA34.9826.7030.9920.46-40.09%
Free Cash Flow Yield1.2%0.3%1.3%2.7%231.73%
Return on Equity3.3%-3.8%3.2%5.5%453.87%
Total Debt$7.26B$6.57B$6.27B$6.16B-9.82%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.